The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery

February 19, 2024 updated by: Yang Zhao, Sixth Affiliated Hospital, Sun Yat-sen University

The Effect of Remote Ischemic Preconditioning on Myocardial Injury After Noncardiac Surgery in Patients at a High Risk of Cardiac Events

This is a multicentre, parallel-group, randomised, sham-controlled, observer blinded trial, assessing the efficacy of remote ischemic preconditioning on preventing myocardial injury after noncardiac surgery.

Study Overview

Detailed Description

This is a multicentre, randomised, sham-controlled, observer blinded trial. Patients at high clinical risk for cardiovascular events and scheduled to undergo major abdominal surgery will be enrolled. A total of 766 patients are randomised (1:1 ratio) to receive RIPC or no RIPC (control) before anaesthesia induction. RIPC will comprise four alternating cycles of cuff inflation for 5 min to 200 mm Hg and deflation for 5 min. In controls, the identical looking cuff will be placed around the arm but not actually inflated for 40 minutes. The primary outcome was myocardial injury after surgery within three days of surgery. The secondary outcomes were peak plasma hs-cTnT and total hs-cTnT release during the first three days after surgery, hs-cTnT above the prognostically important thresholds, length of hospital stay after surgery, and length of stay in the intensive care unit, myocardial infarction, major adverse cardiovascular events, cardiac-related death and all cause death within 30 days, 6 months, 1 year and 2 years after surgery, postoperative morbidity and adverse events within 30 days after surgery.

Study Type

Interventional

Enrollment (Estimated)

766

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Guangdong
      • Guangzhou, Guangdong, China, 510655

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

45 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion criteria

  1. Patients at high clinical risk for cardiovascular events;
  2. Patients scheduled to undergo major abdominal surgery.

Exclusion criteria

  1. Immediate or urgent surgery or surgery where there is insufficient time to perform RIPC.
  2. Abdominal vascular surgery, such as surgery for abdominal aortic aneurysm
  3. Experience of conditions precluding the use of RIPC in both arms
  4. Patients who are being treated with drugs, such as sulphonamide or nicorandil
  5. With contraindications for anaesthetic regimes required in this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Remote ischemic preconditioning
Transient ischemic ischemia consisting of 5-minute ischemia followed by 5-minute perfusion will occur on the upper arm
Remote ischemic preconditioning will consist of four cycles of 5-minute inflation of an blood pressure cuff on the upper arm to 200 mmHg followed by 5-minute deflation. RIPC will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.
Sham Comparator: Sham-remote ischemic preconditioning
Transient ischemic ischemia will not actually occur on the upper arm
The identical looking cuff will be placed around the upper arm but not actually inflated for 40 minutes. The control device's components and external appearance are identical to that of the RIPC. However, as compared to the RIPC, the blood pressure cuff's line of inflation is disconnected such that the cuff cannot be inflated. Control treatment will be performed twice, one at approximately 24 hours before anaesthesia and the other at approximately 1 hour before anaesthesia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial injury after non-cardiac surgery (MINS)
Time Frame: Within the first three days after surgery
Number of participants with MINS, diagnosed according to the criteria established by the American Heart Association in 2021
Within the first three days after surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Myocardial infarction
Time Frame: Within 30 days, 6 months, 1 year and 2 years of surgery
Number of participants with myocardial infarction
Within 30 days, 6 months, 1 year and 2 years of surgery
Major adverse cardiovascular events
Time Frame: Within 30 days, 6 months, 1 year and 2 years of surgery
Cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke
Within 30 days, 6 months, 1 year and 2 years of surgery
Cardiac-related death
Time Frame: Within 30 days, 6 months, 1 year and 2 years of surgery
Death related by cardiac reason
Within 30 days, 6 months, 1 year and 2 years of surgery
All deaths
Time Frame: Within 30 days, 6 months, 1 year and 2 years of surgery
All-cause death after surgery
Within 30 days, 6 months, 1 year and 2 years of surgery
Adverse events
Time Frame: Within 30 days after surgery
Adverse events
Within 30 days after surgery
Participants with the concentration of hs-cTnT reaching/above the prognostically important thresholds
Time Frame: Within the first three days after surgery
Number of participants with the concentration of hs-cTnT reaching/above the prognostically important thresholds
Within the first three days after surgery
Peak concentration of hs-cTnT within the initial 3 days after surgery
Time Frame: Within the first three days after surgery
Peak concentration of high-sensitivity cTnT
Within the first three days after surgery
Total hs-cTnT release within the initial 3 days after surgery (area under the curve)
Time Frame: Within the first three days after surgery
Total hs-cTnT release
Within the first three days after surgery
Length of stay in the intensive care unit
Time Frame: expected 2 days after surgery
Length of intensive care unit stay
expected 2 days after surgery
Length of postoperative stay
Time Frame: expected 6 days after surgery
Length of hospital stay after surgery
expected 6 days after surgery
Major postoperative morbidity
Time Frame: Within 30 days after surgery
Major postoperative morbidity
Within 30 days after surgery

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Acute kidney injury
Time Frame: Within 30 days after surgery
Acute kidney injury
Within 30 days after surgery
Postoperative pulmonary complications
Time Frame: Within 30 days after surgery
Postoperative pulmonary complications
Within 30 days after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Yang Zhao, MD, Sixth SunYetSen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 6, 2023

Primary Completion (Estimated)

December 31, 2025

Study Completion (Estimated)

December 31, 2027

Study Registration Dates

First Submitted

February 6, 2023

First Submitted That Met QC Criteria

February 14, 2023

First Posted (Actual)

February 17, 2023

Study Record Updates

Last Update Posted (Estimated)

February 21, 2024

Last Update Submitted That Met QC Criteria

February 19, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • E2022236

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

The data shown in the tables or figures in the published paper will be shared with other researchers on reasonable requests. Reasonable requests for data sharing should be made to the corresponding author and will be handled in line with the data access and sharing policy of the Human Genetic Resource Administration of China.

IPD Sharing Time Frame

from 6 months to 36 months after publication

IPD Sharing Access Criteria

Reasonable requests for data sharing should be made to the corresponding author and will be handled in line with the data access and sharing policy of the Human Genetic Resource Administration of China.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Myocardial Injury

Clinical Trials on Remote ischemic preconditioning

3
Subscribe